<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Although some studies have suggested a direct action of <z:chebi fb="0" ids="9753">troglitazone</z:chebi> on vascular cells, its effects on <z:e sem="disease" ids="C0011875" disease_type="Disease or Syndrome" abbrv="">diabetic vascular diseases</z:e> have not been reported </plain></SENT>
<SENT sid="1" pm="."><plain>We therefore investigated the effect of <z:chebi fb="0" ids="9753">troglitazone</z:chebi> on <z:mp ids='MP_0002959'>microalbuminuria</z:mp> in patients with incipient diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: A total of 30 patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> associated with <z:mp ids='MP_0002959'>microalbuminuria</z:mp> (urinary albumin-to-<z:chebi fb="0" ids="16737">creatinine</z:chebi> ratio [ACR] [milligrams per gram <z:chebi fb="0" ids="16737">creatinine</z:chebi>] ranging from 30 to 300 mg/g <z:chebi fb="0" ids="16737">creatinine</z:chebi>) were studied </plain></SENT>
<SENT sid="3" pm="."><plain>They were randomly divided into two groups: patients treated with <z:chebi fb="0" ids="6801">metformin</z:chebi> (500 mg/day, n = 13) or with <z:chebi fb="0" ids="9753">troglitazone</z:chebi> (400 mg/day, n = 17) for 12 weeks </plain></SENT>
<SENT sid="4" pm="."><plain>ACR, <z:chebi fb="23" ids="18059">lipid</z:chebi> profile, blood pressure, glycated <z:chebi fb="0" ids="35143">hemoglobin</z:chebi>, and plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> during meal-load tests were measured every 4 weeks </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Anthropometric indices (BMI and percent fat), <z:chebi fb="23" ids="18059">lipid</z:chebi> profile, and blood pressure did not change with either treatment </plain></SENT>
<SENT sid="6" pm="."><plain>Fasting and postmeal <z:chebi fb="105" ids="17234">glucose</z:chebi> levels decreased similarly in the two groups </plain></SENT>
<SENT sid="7" pm="."><plain>Decrements in glycated <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> were greater in the <z:chebi fb="0" ids="6801">metformin</z:chebi> group at 4 and 8 weeks after the initiation of treatment (P &lt; 0.05) </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="9753">Troglitazone</z:chebi> reduced ACR (median [25-75th percentiles]) from 70 (49-195) to 40 (31-90) mg/g <z:chebi fb="0" ids="16737">creatinine</z:chebi> at 4 weeks (P = 0.021) and maintained these reduced levels throughout the treatment period (8 weeks: 35 [26-68], P = 0.007; 12 weeks: 43 [26-103], P = 0.047) </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> did not change ACR throughout the 12 weeks </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: <z:chebi fb="0" ids="9753">Troglitazone</z:chebi> ameliorated <z:mp ids='MP_0002959'>microalbuminuria</z:mp> in diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>Furthermore, our findings suggest that <z:chebi fb="0" ids="9753">troglitazone</z:chebi> has some effects on vascular cells other than lowering plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> levels </plain></SENT>
<SENT sid="12" pm="."><plain><z:chebi fb="0" ids="9753">Troglitazone</z:chebi> might be useful for <z:e sem="disease" ids="C0011875" disease_type="Disease or Syndrome" abbrv="">diabetic angiopathy</z:e>, including <z:hpo ids='HP_0000112'>nephropathy</z:hpo> and <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo> </plain></SENT>
</text></document>